The latest update is out from InMed Pharmaceuticals ( (INM) ).
InMed Pharmaceuticals has welcomed Dr. Barry Greenberg, a prominent Alzheimer’s researcher from Johns Hopkins University, to its Scientific Advisory Board. Dr. Greenberg’s extensive experience in Alzheimer’s research is expected to be pivotal as InMed advances its INM-901 drug candidate towards clinical trials, aiming to address unmet medical needs in Alzheimer’s treatment through innovative small molecule drug development.
See more data about INM stock on TipRanks’ Stock Analysis page.
